ALK3 (BMPR1A) siRNA Set I(B04-911)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :ALK3 (BMPR1A) is a pool of three individual synthetic siRNA duplexes designed to knock-down human ALK3 (BMPR1A) mRNA expression. Each siRNA is 19-25 bases in length.
Specificity :ALK3 (BMPR1A) siRNAs are designed to specifically knock-down human ALK3 (BMPR1A) expression.
Formulation :The siRNAs are supplied as a lyophilized powder and shipped at room temperature.
Reconstitution Protocol :Briefly centrifuge the tubes (maximum RCF 4,000g) to collect lyophilized siRNA at the bottom of the tube. Resuspend the siRNA in 50 ul of DEPC-treated water (supplied by researcher), which results in a 1x stock solution (10 uM). Gently pipet the solution 3-5 times to mix and avoid the introduction of bubbles. Optional: aliquot 1x stock solutions for storage.
Storage and Stability :The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the lyophilized and resuspended siRNAs are stored at or below -20oC. After resuspension, siRNA stock solutions ≥2 uM can undergo up to 50 freeze-thaw cycles without significant degradation. For long-term storage, it is recommended that the siRNA is stored at -70oC. For most favorable performance, avoid repeated Handling and multiple freeze/thaw cycles.
Format :Lyophilized powder
Gene Aliases :ALK3; BMPR1A; 10q23del; ACVRLK3; CD292; SKR5
Scientific Background :BMPR1A (also known as bone morphogenetic protein receptor 1A) is a member of the transmembrane serine/threonine kinase family that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. BMPR1A act as a minor susceptibility gene for PTEN-mutation-negative Cowden syndrome. BMPR1A regulates the PTEN protein levels by decreasing PTEN's association with the degradative pathway (1). BMPR1A trafficking plays a significant role in FOP pathogenesis and is also involved in human T-cell differentiation (2)
1. Waite, K. A. et.al: BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum. Molec. Genet. 12: 679-684, 2003.
2. Cejalvo, T. et.al: Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology 121: 94-104, 2007.
Product Sheets (By Lot #) :
Research Areas :AKT/PKB Pathway, Angiogenesis, Cancer, Cardiovascular Disease, JAK/STAT Pathway, Neurobiology, Ser/Thr Kinases, Cancer, Neurobiology, Cardiovascular Disease, AKT/PKB Pathway, JAK/STAT Pathway, Angiogenesis, Ser/Thr Kinases